Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
GHRP-6 activates the GHS-R1a (ghrelin) , releasing GH independently of and somatostatin in animal models. Beyond GH release, rodent research has described pro-survival cytoprotective effects across hepatic, intestinal, renal, lung, and cardiac injury models.
02
Research applications
- Growth hormone secretion pharmacology
- Cytoprotection and ischaemia / reperfusion research
- Cardiomyopathy and chemotherapy-cardiotoxicity research
- GHRP reference standard
Evidence at a glance
What's behind this profile
3 citations · 1993–2024
- Animal
- 2
- Other
- 1
Studies in rodents or other animal models.
Studies that did not match the categories above.
Publication years
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 00
- 01
- 02
- 03
- 04
- 05
- 06
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6)
1993
Micic D et al. · Journal of Pediatric Endocrinology
- Model
- Mixed — animal pharmacology with human-subject extension in obesity
- Sample
- Not reported in abstract
Reported that GHRP-6 releases GH largely independently of hypothalamic and somatostatin and acts as a potent releaser in obesity contexts.
Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure
2006
Cibrián D et al. · Clinical Science
- Model
- In vitro cell-culture + in vivo rat ischaemia / reperfusion organ-failure model
- Sample
- Not reported in abstract
GHRP-6 enhanced epithelial and was associated with reduced hepatic, intestinal, lung, and renal injury in the rat I/R organ-failure model used.
Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms
2024
Berlanga-Acosta J et al. · Frontiers in Pharmacology
- Model
- In vivo — rat model of doxorubicin-induced cardiomyopathy
- Sample
- Not reported in abstract
GHRP-6 co-administered with doxorubicin was associated with preserved cardiac function, reduced extra-myocardial organ damage, and activation of cellular survival pathways in the rat model used.
Evidence caveats
- GHRP-6 is not approved as a medicine. Human pharmacology evidence is limited to early-phase studies.
- Cytoprotection and organ-failure data are predominantly from rodent models; extrapolation to clinical outcomes is not established.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Maintain batch traceability for reference-standard comparison work.
- Avoid repeated cycles where not protocol-supported.
- Research-only inventory must be clearly separated from clinical material.